Literature DB >> 2108450

Leukotrienes and inflammation.

S D Brain1, T J Williams.   

Abstract

The leukotrienes are synthesized from essential fatty acids via a 5-lipoxygenase enzyme. Most is known about the four-series leukotrienes derived from arachidonic acid. Leukotriene B4 is a potent chemotactic agent for leukocytes and it induces neutrophil-dependent increased microvascular permeability. Leukotrienes C4, D4 and E4 are bronchoconstrictors; and potent mediators of microvascular tone and permeability. The leukotrienes have been suggested to have a role in many inflammatory conditions in man in the skin (e.g. psoriasis), the lung (e.g. allergic asthma), joints (e.g. rheumatoid arthritis) and in the heart (e.g. myocardial infarction). Drugs which inhibit the generation and the actions of leukotrienes are under development and are being tested clinically as potential anti-inflammatory agents.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2108450     DOI: 10.1016/0163-7258(90)90035-z

Source DB:  PubMed          Journal:  Pharmacol Ther        ISSN: 0163-7258            Impact factor:   12.310


  13 in total

1.  Mesenteric blood flow is related to disease activity and risk of relapse in ulcerative colitis: a prospective follow up study.

Authors:  D Ludwig; S Wiener; A Brüning; K Schwarting; G Jantschek; K Fellermann; M Stahl; E F Stange
Journal:  Gut       Date:  1999-10       Impact factor: 23.059

2.  Divergent mechanisms of action of the inflammatory cytokines interleukin 1-beta and tumour necrosis factor-alpha in mouse cremasteric venules.

Authors:  R E Young; R D Thompson; S Nourshargh
Journal:  Br J Pharmacol       Date:  2002-12       Impact factor: 8.739

3.  A study of granulocyte respiratory burst in patients with allergic bronchial asthma.

Authors:  L Vargas; P J Patiño; F Montoya; A C Vanegas; A Echavarría; D García de Olarte
Journal:  Inflammation       Date:  1998-02       Impact factor: 4.092

4.  Assessment of the pharmacokinetic interaction between zileuton and digoxin in humans.

Authors:  W M Awni; Z Hussein; J H Cavanaugh; G R Granneman; L M Dubé
Journal:  Clin Pharmacokinet       Date:  1995       Impact factor: 6.447

5.  Leukotriene biosynthesis inhibition by aryl and aroyl substituted naphthoquinones.

Authors:  D M Roland; W M Macchia; K S Grim; E F Kimble; D H White; T J Kowalski
Journal:  Agents Actions       Date:  1991-09

6.  Pharmacokinetic interactions between zileuton and prednisone.

Authors:  W M Awni; J H Cavanaugh; T B Tzeng; G Witt; G R Granneman; L M Dubé
Journal:  Clin Pharmacokinet       Date:  1995       Impact factor: 6.447

7.  The pharmacokinetic and pharmacodynamic interactions between the 5-lipoxygenase inhibitor zileuton and the cyclo-oxygenase inhibitor naproxen in human volunteers.

Authors:  W M Awni; R A Braeckman; J H Cavanaugh; C S Locke; P J Linnen; G R Granneman; L M Dubé
Journal:  Clin Pharmacokinet       Date:  1995       Impact factor: 6.447

8.  Early vascular permeability in murine experimental peritonitis is co-mediated by resident peritoneal macrophages and mast cells: crucial involvement of macrophage-derived cysteinyl-leukotrienes.

Authors:  Elzbieta Kolaczkowska; Susan Shahzidi; Rolf Seljelid; Nico van Rooijen; Barbara Plytycz
Journal:  Inflammation       Date:  2002-04       Impact factor: 4.092

9.  Circulating cytotoxic immune components in dominant Charcot-Marie-Tooth syndrome.

Authors:  L L Williams; B T Shannon; F S Wright
Journal:  J Clin Immunol       Date:  1993-11       Impact factor: 8.317

10.  Effect of the leukotriene receptor antagonists FPL 55712, LY 163443, and MK-571 on the elimination of cysteinyl leukotrienes in the rat.

Authors:  C Denzlinger; M Grimberg; A Kapp; C Haberl; W Wilmanns
Journal:  Br J Pharmacol       Date:  1991-04       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.